iX Biopharma Ltd. (SGX:42C)

iX Biopharma Statistics

Total Valuation

iX Biopharma has a market cap or net worth of SGD 207.26 million. The enterprise value is 208.23 million.

Market Cap	207.26M
Enterprise Value	208.23M

Important Dates

The last earnings date was Wednesday, February 4, 2026.

Earnings Date	Feb 4, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+9.14%
Shares Change (QoQ)	+3.15%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	607.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	28.67
PB Ratio	50.14
P/TBV Ratio	53.46
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-35.01
EV / Sales	28.80
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-54.62

Financial Position

The company has a current ratio of 1.05, with a Debt / Equity ratio of 1.63.

Current Ratio	1.05
Quick Ratio	0.91
Debt / Equity	1.63
Debt / EBITDA	n/a
Debt / FCF	-1.77
Interest Coverage	-9.66

Financial Efficiency

Return on equity (ROE) is -155.52% and return on invested capital (ROIC) is -37.28%.

Return on Equity (ROE)	-155.52%
Return on Assets (ROA)	-24.84%
Return on Invested Capital (ROIC)	-37.28%
Return on Capital Employed (ROCE)	-72.67%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	206,543
Profits Per Employee	-169,914
Employee Count	35
Asset Turnover	0.50
Inventory Turnover	5.46

Taxes

In the past 12 months, iX Biopharma has paid 2,000 in taxes.

Income Tax	2,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +852.38% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+852.38%
50-Day Moving Average	0.18
200-Day Moving Average	0.08
Relative Strength Index (RSI)	50.91
Average Volume (20 Days)	15,346,945

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, iX Biopharma had revenue of SGD 7.23 million and -5.95 million in losses. Loss per share was -0.01.

Revenue	7.23M
Gross Profit	2.03M
Operating Income	-5.76M
Pretax Income	-5.95M
Net Income	-5.95M
EBITDA	-5.36M
EBIT	-5.76M
Loss Per Share	-0.01

Balance Sheet

The company has 5.77 million in cash and 6.73 million in debt, with a net cash position of -966,000.

Cash & Cash Equivalents	5.77M
Total Debt	6.73M
Net Cash	-966,000
Net Cash Per Share	n/a
Equity (Book Value)	4.13M
Book Value Per Share	0.00
Working Capital	434,000

Cash Flow

In the last 12 months, operating cash flow was -3.73 million and capital expenditures -82,000, giving a free cash flow of -3.81 million.

Operating Cash Flow	-3.73M
Capital Expenditures	-82,000
Free Cash Flow	-3.81M
FCF Per Share	n/a

Margins

Gross margin is 28.05%, with operating and profit margins of -79.64% and -82.27%.

Gross Margin	28.05%
Operating Margin	-79.64%
Pretax Margin	-82.24%
Profit Margin	-82.27%
EBITDA Margin	-74.12%
EBIT Margin	-79.64%
FCF Margin	n/a

Dividends & Yields

iX Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.14%
Shareholder Yield	-9.14%
Earnings Yield	-2.87%
FCF Yield	-1.84%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

iX Biopharma has an Altman Z-Score of -8.03 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.03
Piotroski F-Score	3